Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018–2025: A cross-sectional analysis

European Journal of Cancer 2026

View at publisher

Authors: Guanqiao Li, Yiwen Pu, C. Chen, Aaron Seth Kesselheim, Ariadna Tibau

DOI: 10.1016/j.ejca.2026.116907

Cited by: 1

References: 37

Fields of Study & Subjects

Statistical Methods in Clinical Trials Economic and Financial Impacts of Cancer Advanced Causal Inference Techniques

References 37